The Lithuanian pharmaceutical market is estimated at € 601million. According to BMI non-communicable conditions such as cardiovascular disease and cancer dynamics will make the country attractive to innovative drug-makers. In 2010-2015 Lithuania’s economy has been steadily growing and in 2014 and in 2015 its national currency was replaced by the Euro. Lithuania’s biotechnology sector has been recognised as one of the most developed in the Central and Eastern Europe. A small number of commercial enterprises specialise in the development of biotechnological healthcare products.